NCT06366802进行中（未招募）不适用
Cohort Construction and Prognostic Model Construction for Multiple Myeloma
The First Affiliated Hospital of Soochow University1 个研究点 分布在 1 个国家目标入组 1,000 人开始时间: 2022年5月3日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 1,000
- 试验地点
- 1
- 主要终点
- Overall survival
研究概览
简要总结
Multiple myeloma (MM) is a disease caused by malignant plasma cell proliferation disorder. Survival outcomes continue to vary widely even within uniformly treated clinical trial populations. How to construct a clinical prognosis model of MM through real-world data to guide the selection of treatment options, standardize patient management, and improve survival expectations, is a major problem that needs to be solved urgently. It is necessary to build an MM-specific cohort in China to comprehensively understand the characteristics of MM patients, explore treatment options, and improve prognostic factors for survival outcomes.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients were diagnosed as multiple myeloma from January 1, 2008 (the diagnostic criteria are based on "Chinese Guidelines for the Diagnosis and Treatment of Multiple Myeloma (Revised in 2020)").
排除标准
- •Long-term follow-up information for patients is not available for any reason, such as not being available or having a serious concomitant disease.
结局指标
主要结局
Overall survival
时间窗: 5 years
Overall survival is defined as the time from being treated to death from any cause.
次要结局
- Progression free survival(PFS)(5years)
研究者
研究点 (1)
Loading locations...
相似试验
终止
1 期
ON 123300 (Narazaciclib) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple MyelomaRelapsed and/or Refractory Multiple MyelomaNCT06351644Adriana Rossi2
已完成
不适用
High Dose Therapy Followed by Autologous Transplantation for Myeloma Patients With Severe Renal ImpairmentMultiple MyelomaRenal FailureNCT03234335Centre Hospitalier Universitaire de Saint Etienne50
尚未招募
早期 1 期
An Clinical Study of NKG2D-CAR-NK Cells for the Treatment of Refractory Recurrent Multiple MyelomaMultiple MyelomaNCT06379451Changzhou No.2 People's Hospital9
已完成
不适用
The Molecular Characterization of Multiple Myeloma at RelapseMultiple MyelomaNCT00639054Rigshospitalet, Denmark134
终止
不适用
CAR-T Cells Therapy in Relapsed/Refractory Multiple MyelomaRelapsed/Refractory Multiple Myeloma(MM)NCT03473496Zhujiang Hospital2